Numerate and Intellikine Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha

SAN BRUNO & LA JOLLA, Calif.--(BUSINESS WIRE)-- Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine’s unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate’s powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.

“Numerate has demonstrated that its data-driven drug design technology can deliver high quality, novel chemical scaffolds rapidly and cost-effectively,” said Troy Wilson, President and Chief Executive Officer of Intellikine. “These impressive results significantly expand our chemical diversity and further strengthen our proprietary position in an exciting area of anti-cancer research.”

“It was a privilege to work with Intellikine, which is moving rapidly ahead against a very promising target in cancer,” stated Guido Lanza, President and Chief Executive Officer of Numerate. “Our collaboration illustrates the power of our technology platform to add value to a company’s pipeline and intellectual property position.”

To discover the novel lead compounds, Numerate scientists ran their platform on Amazon’s Elastic Compute Cloud (EC2), allowing them to search through hundreds of millions of compounds to identify those with the highest probability of activity against PI3K. Those compounds were then synthesized and their inhibitory activity and other properties verified in the laboratory.

About Numerate

Numerate is a privately held biotechnology company focused on making the drug design process more data-driven, efficient and predictable. Numerate’s platform combines advances in computer science and statistics with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields. For more information, please visit www.numerate.com.

About Intellikine

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine’s most advanced program, INK128, a selective TORC1/2 inhibitor for the treatment of cancer, is currently in a Phase 1 clinical trial in patients with advanced solid tumors. In addition, Intellikine was recently awarded a $1 million grant from the Multiple Myeloma Research Foundation to advance INK128 as a potential treatment for patients with multiple myeloma. Intellikine is also advancing a first-in-class PI3Kalpha-selective inhibitor, INK1117, which is currently being prepared for human clinical trials in cancer. Beyond INK128 and INK1117, Intellikine has generated one of the leading pipelines of drug candidates against important therapeutic targets in this pathway. Intellikine has raised $41 million from an outstanding group of life science investors, including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital. For more information, please visit the company’s website at www.intellikine.com.



CONTACT:

Numerate, Inc.
Guido Lanza, 650-515-3254
Chief Executive Officer
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.